18 participants
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2025-10-29
- Start Date:
- 2020-03-04
- Completion:
- 2022-09-30
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
- DRUG
- BIOLOGICAL